牛牛AI助理已提取核心訊息
On August 15, 2024, Conduit Pharmaceuticals Inc. received two deficiency notices from The Nasdaq Stock Market LLC. The first notice indicated that the company's common stock did not meet the Nasdaq's minimum market value of publicly held shares requirement of $15 million over the past 30 consecutive business days. The second notice stated that the company also failed to comply with the minimum market value of listed securities requirement of $50 million. Conduit Pharmaceuticals has been given 180 days, until February 11, 2025, to regain compliance with both requirements. If the company fails to meet these requirements within the given timeframe, its securities may be delisted from Nasdaq. The company may also consider transferring its securities to The Nasdaq Capital Market if it meets the continued listing requirements there. In a separate event, Conduit Pharmaceuticals became aware of undisclosed share dispositions by a director through a subsidiary and a third-party pledge arrangement involving approximately 31% of its outstanding common stock. In response, the company has formed two independent committees to review these matters and determine necessary actions.
On August 15, 2024, Conduit Pharmaceuticals Inc. received two deficiency notices from The Nasdaq Stock Market LLC. The first notice indicated that the company's common stock did not meet the Nasdaq's minimum market value of publicly held shares requirement of $15 million over the past 30 consecutive business days. The second notice stated that the company also failed to comply with the minimum market value of listed securities requirement of $50 million. Conduit Pharmaceuticals has been given 180 days, until February 11, 2025, to regain compliance with both requirements. If the company fails to meet these requirements within the given timeframe, its securities may be delisted from Nasdaq. The company may also consider transferring its securities to The Nasdaq Capital Market if it meets the continued listing requirements there. In a separate event, Conduit Pharmaceuticals became aware of undisclosed share dispositions by a director through a subsidiary and a third-party pledge arrangement involving approximately 31% of its outstanding common stock. In response, the company has formed two independent committees to review these matters and determine necessary actions.
2024年8月15日，Conduit Pharmaceuticals Inc.收到了來自Nasdaq股票市場的兩份違規通知。第一份通知指出，公司的普通股在過去30個連續的業務日中未達到Nasdaq的最低市值要求，即1,500萬美元。第二份通知表明，公司還未能遵守上市證券最低市值要求的5,000萬美元。Conduit Pharmaceuticals被給予180天的時間，直到2025年2月11日，以符合這兩個要求。如果公司未能在規定的時間內達到這些要求，其證券可能會被從Nasdaq除牌。如果符合Nasdaq Capital市場的持續上市要求，該公司還可以考慮將其證券轉移到該市場。在另一件事件中，Conduit Pharmaceuticals發現一位董事通過子公司和第三方質押安排出售了約31%的未流通普通股。作爲回應，該公司成立了兩個獨立委員會審查這些事項，並判斷必要的行動。
2024年8月15日，Conduit Pharmaceuticals Inc.收到了來自Nasdaq股票市場的兩份違規通知。第一份通知指出，公司的普通股在過去30個連續的業務日中未達到Nasdaq的最低市值要求，即1,500萬美元。第二份通知表明，公司還未能遵守上市證券最低市值要求的5,000萬美元。Conduit Pharmaceuticals被給予180天的時間，直到2025年2月11日，以符合這兩個要求。如果公司未能在規定的時間內達到這些要求，其證券可能會被從Nasdaq除牌。如果符合Nasdaq Capital市場的持續上市要求，該公司還可以考慮將其證券轉移到該市場。在另一件事件中，Conduit Pharmaceuticals發現一位董事通過子公司和第三方質押安排出售了約31%的未流通普通股。作爲回應，該公司成立了兩個獨立委員會審查這些事項，並判斷必要的行動。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了